News & Articles

Discover the importance of high-throughput and robust methodologies for finding ‘needle-in-the-haystack’ therapeutic antibodies

Study enrolled 43,538 participants, with 42% having diverse backgrounds, and no serious safety concerns have been observed; Safety and additional efficacy data continue to be collected

Party during Neuroscience 2018 celebrates the importance of effective conversation between scientists and manufacturers

Discover how AFABILITY founder Dr. Alison Gray is enabling the transition from animal-derived to non-animal-derived antibodies

The StarBright Blue 700, StarBright Violet 440 and StarBright Violet 610 dyes aim to offer maximal brightness for improved resolution

The platform can directly isolate IgG genes from B cells of immunized animals

Company’s latest test enables differential diagnosis between COVID-19, flu and RSV infection

Which new products made the most difference to your lab work this year?

The study leverages the Tapestri Platform to illustrate the single-cell atlas of acute myeloid leukemia (AML) with multi-omics, describing the clonality underlying therapeutic resistance

Veklury is first FDA-approved treatment for COVID-19 in the US, and aims to shorten time to recovery by five days

The hypercube algorithm aims to enable regular, cost-effective screening in multiple contexts

Experts share novel techniques for accelerating monoclonal antibody discovery and development to bring hope to COVID-19 patients

The Leo Foundation-funded study for first time identifies Sbi as the molecule that induces rapid release of Interleukin-33

The test uses a convolutional neural network to classify microscopy images of single intact particles of different viruses

Availability of the new IgM blood test on the ARCHITECT and Alinity platforms is part of Abbott's effort to offer tests across the disease progression of COVID-19

Easy-to-use test, which doesn't require specialized laboratory personnel or instruments, promises flexibility to test in locations that benefit from immediate results

Summa Equity Fund II acquires a majority stake in Sengenics, a functional proteomics company with a unique technology for production of full-length, correctly folded and functional proteins

Antibodies available are specific for S1, S2 and receptor-binding domain regions of SARS-CoV-2 Spike protein

Join us on Wednesday, October 28, to learn how SpyTag-SpyCatcher technology enables site-directed conjugation and rapid assembly of different antibody format